Cerebrovascular resistance: Effects on cognitive decline, cortical atrophy, and progression to dementia

Brain

Volumn 140, Issue 7, 2017, Pages 1987-2001

  Yew, Belinda ^a   Nation, Daniel A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; beta amyloid; blood pressure; cerebral blood flow; dementia biomarkers

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; AMYLOID; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; SPIN LABEL;

ADULT; AGED; AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTERIAL SPIN LABELING; ARTICLE; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN PERFUSION; BRAIN REGION; CEREBROVASCULAR RESISTANCE INDEX; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DISEASE COURSE; DISEASE PREDISPOSITION; ELEVATED BLOOD PRESSURE; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GERIATRIC DEPRESSION SCALE; HUMAN; INFERIOR PARIETAL CORTEX; INFERIOR TEMPORAL CORTEX; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEMORY; MINI MENTAL STATE EXAMINATION; NERVOUS SYSTEM PARAMETERS; NORTH AMERICAN; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; REY AUDITORY VERBAL LEARNING TEST; TASK PERFORMANCE; TRAIL MAKING TEST; WHITE MATTER; ATROPHY; BLOOD PRESSURE; BRAIN; BRAIN CORTEX; COGNITIVE DEFECT; COMPLICATION; METABOLISM; NERVE CELL; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; VASCULAR RESISTANCE; VASCULARIZATION;

AGED; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; ATROPHY; BLOOD PRESSURE; BRAIN; CEREBRAL CORTEX; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; ETHYLENE GLYCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROIMAGING; NEURONS; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; SPIN LABELS; VASCULAR RESISTANCE; WHITE MATTER;

EID: 85022327849     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awx112     Document Type: Article

References (72)

1. Alsop DC, Dai W, Grossman M, Detre JA. Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease. J Alzheimers Dis 2010; 20: 871-80
2. Alvarez JA, Emory E. Executive function and the frontal lobes: a metaanalytic review. Neuropsychol Rev 2006; 16: 17-42
3. Andersson C, Lindau M, Almkvist O, Engfeldt P, Johansson SE, Eriksdotter Jönhagen M. Identifying patients at high and low risk of cognitive decline using Rey Auditory Verbal Learning Test among middle-aged memory clinic outpatients. Dement Geriatr Cogn Disord 2006; 21: 251-9
4. Ashendorf L, Jefferson AL, ÓäôConnor MK, Chaisson C, Green RC, Stern RA. Trail making test errors in normal aging, mild cognitive impairment, and dementia. Arch Clin Neuropsychol 2008; 23: 129-37
5. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 2009; 11: 143
6. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Methodol 1995; 57: 289-300
7. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000; 343: 450-6
8. Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993; 33: 403-8
9. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000; 21: 153-60
10. Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, et al. Independent contribution of temporal b-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 2011; 134: 798
11. Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol 2016; 80: 247-58
12. Dai WY, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gachm HM. Mild cognitive impairment and Alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology 2009; 250: 856-66
13. den Abeelen AS, Lagro J, van Beek AH, Claassen JA. Impaired cerebral autoregulation and vasomotor reactiity in sporadic Alzheimer's disease. Curr Alzheimer Res 2014; 11: 11-17
14. Dickerson BC, Wolk DA; Alzheimer's Disease Neuroimaging Initiative. Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry 2011; 82: 45-51
15. Drachman DA. The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement 2014; 10: 372-80
16. Du AT, Jahng GH, Hayasaka S, Kramer JH, Rosen HJ, Gorno-Tempini ML, et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology 2006; 67: 1215-20
17. Fischl B, Salat DH, van Der Kouwe AJ, Makris N, Segonne F, Quinn BT, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004; 23 (Suppl 1): S69-84
18. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
19. Gietl AF, Warnock G, Riese F, Kälin AM, Saake A, Gruber E, et al. Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. Neurobiol Aging 2015; 36: 1619-28
20. Hajjar I, Sorond F, Lipsitz LA. Apolipoprotein E, Carbon Dioxide vasoreactivity, and cognition in older adults: effect of hypertension. J Am Geriatr Soc 2015; 63: 276-81
21. Hajjar I, Zhao P, Alsop D, Novak V. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension 2010; 56: 859-64
22. Han BH, Zhou ML, Johnson AW, Singh I, Liao F, Vellimana AK, et al. Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. Proc Natl Acad Sci USA 2015; 112: E881-90
23. Hughes TM, Kuller LH, Barinas-Mitchell EM, McDade EM, Klunk WE, Cohen AD, et al. Arterial stiffness and b-amyloid progression in nondemented elderly adults. JAMA Neurol 2014; 71: 562-8
24. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-60
25. Iliff JJ, Goldman SA, Nedergaard M. Implications of the discovery of brain lymphatic pathways. Lancet Neurol 2015; 14: 977
26. Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun 2016; 7: 11934
27. Jedynak BM, Lang A, Liu B, Katz E, Zhang Y, Wyman BT, et al. A computational neurodegenerative disease progression score: method and results with the AlzheimerfflÄôs disease neuroimaging initiative cohort. Neuroimage 2012; 63: 1478-86
28. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET and florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012; 53: 378-84
29. Kamper AM, Spilt A, de Craen AJM, van Buchem MA, Westendorp RGJ, Blauw GJ. Basal cerebral blood flow is dependent on the nitric oxide pathway in elderly but not in young healthy men. Exp Gerontol 2004; 39: 1245-8
30. Kanekiyo T, Xu H, Bu G. ApoE and Ab in Alzheimer's disease: accidental encounters or partners? Neuron 2014; 81: 740-54
31. Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 2014; 76: 845-61
32. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011; 32: 1207-18
33. Langbaum JB, Chen K, Launer LJ, Fleisher AS, Lee W, Liu X, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging 2012; 33: 827.e11-19
34. Li H, Guo Q, Inoue T, Polito VA, Tabuchi K, Hammer RE, et al. Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. Mol Neurodegener 2014; 9: 28
35. Liu J, Zhu YS, Khan MA, Brunk E, Martin-Cook K, Weiner MF, et al. Global brain hypoperfusion and oxygenation in amnestic mild cognitive impairment. Alzheimers Dement 2014; 10: 162-70
36. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545-51
37. Mattson RH, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, et al. Association of brain amyloid-ß with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain 2014; 137: 1550-61
38. Moll J, Oliveira-Souza Rd, Moll FT, Bramati IE, Andreiuolo PA. The cerebral correlates of set-shifting: an fMRI study of the trail making test. Arq Neuropsiquiatr 2002; 60: 900-5
39. Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, et al. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp 2009; 30: 2766-88
40. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-14
41. Musiek ES, Chen Y, Korczykowski M, Saboury B, Martinez PM, Reddin JS, et al. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement 2012; 8: 51-9
42. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci 2015; 18: 800-6
43. Nation DA, Delano-Wood L, Bangen KJ, Wierenga CE, Jak AJ, Hansen LA, et al. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer's disease. J Alzheimers Dis 2012; 30: 595-603
44. Nation DA, Edland SD, Bondi MW, Salmon DP, Delano-Wood L, Peskind ER, et al. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology 2013a; 81: 2024-7
45. Nation DA, Edmonds EC, Bangen KJ, Delano-Wood L, Scanlon BK, Han SD, et al. Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. JAMA Neurol 2015a; 72: 546-53
46. Nation DA, Ho J, Yew B. Older adults taking AT1-receptor blockers exhibit reduced cerebral amyloid retention. J Alzheimers Dis 2015b; 50: 779-89
47. Nation DA, Wierenga CE, Clark LR, Dev SI, Stricker NH, Jak AJ, et al. Cortical and subcortical cerebrovascular resistance index in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2013b; 36: 689-98
48. Nedergaard M. Garbage truck of the brain. Science 2013; 340: 1529
49. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 2002; 283: H315-23
50. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487-99
51. Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev 2006; 30: 730-48
52. Rey A. Lexamen psychologique dans les cas dencéphalopathie traumatique. Arch Psychol 1941; 28: 215-85
53. Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R, Park DC. Risk factors for b-Amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 2013; 70: 600-6
54. Schoenberg MR, Dawson KA, Duff K, Patton D, Scott JG, Adams RL. Test performance and classification statistics for the Rey Auditory Verbal Learning Test in selected clinical samples. Arch Clin Neuropsychol 2006; 21: 693-703
55. Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging 2009; 21: 239-51
56. Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, et al. Dissociable intrinsic connectivity networks for saliene processing and executive control. J Neurosci 2007; 27: 2349-56
57. Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, D'Angelo G, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Ab42. J Neurosci 2010; 30: 17035-40
58. Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement 2015; 11: 710-17
59. Sole M, Minano-Molina AJ, Unzeta M. A cross-talk between Abeta and endothelial SSAO/VAP-1 accelerates vascular damage and Abeta aggregation related to CAA-AD. Neurobiol Aging 2015; 36: 762-75
60. Spreen O, Strauss E. A compendium of neuropsychological tests. 2nd edn. New York, NY: Oxford University Press; 1998
61. Suri S, Mackay CE, Kelly ME, Germuska M, Tunbridge EM, Frisoni GB, et al. Reduced cerebrovascular reactivity in young adults carrying the APOE 4 allele. Alzheimers Dement 2015; 11: 648-57.e1
62. Thal DR, Rüb U, Orantes M, Braak H. Phases of abeta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-800
63. Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, et al. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 2003; 23: 994
64. Tosun D, Schuff N, Jagust W, Weiner MW. Discriminative power of arterial spin labeling magnetic resonance imaging and 18FFluorodeoxyglucose positron emission tomography changes for Amyloid-b-Positive subjects in the Alzheimer's disease continuum. Neurodegener Dis 2016; 16: 87-94
65. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology 2009; 72: 368-74
66. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol 2009; 118: 87-102
67. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-ß peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008; 18: 253-66
68. White RP, Deane C, Vallance P, Markus HS. Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke 1998; 29: 467
69. Wolters FJ, de Bruijn RF, Hofman A, Koudstaal PJ, Ikram MA. cerebral vasoreactivity, apolipoprotein E, and the risk of dementia: a population-based study. Arterioscler Thromb Vasc Biol 2016; 36: 204-10
70. Wu W, Brickman AM, Luchsinger J, Ferrazzano P, Pichiule P, Yoshita M, et al. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol 2008; 64: 698-706
71. Zakzanis KK, Mraz R, Graham SJ. An fMRI study of the trail making test. Neuropsychologia 2005; 43: 1878-86
72. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-38